This house believes that multiple-fraction radiotherapy is a barrier to referral for palliative radiotherapy for bone metastases

Current Oncology

Volumn 9, Issue 3, 2002, Pages 60-66

  Chow, Edward ^a   Coia, L ^f   Wu, J ^b   Janjan, N ^c   Kirkbride, P ^d   Hoskin, P ^e   Blitzer, P ^f  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE METASTASIS; CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; MEDICAL SOCIETY; PALLIATIVE THERAPY; REVIEW; UNITED STATES;

EID: 0036969088     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Janjan NA. An emerging respect for palliative care in radiation oncology. J Palliat Med 1998;1:83-8.
2. SBU - The Swedish Council on Technology Assessment in Health Care. Radiotherapy practices in Sweden compared to the scientific evidence. Acta Oncol 1996;35(suppl 6):89-97.
3. Janjan NA. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997;80:1628-45.
4. Dale RG, Jones B. Radiobiologically based assessments of the net costs of fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1996;36:739-46.
5. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9.
6. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-9.
7. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
8. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
9. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
10. Lipton A, Thedault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
11. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91.
12. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997;80:1668-73.
13. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-9.
14. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998;16:1218-25.
15. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14:2552-9.
16. Hillner BE. The role of bisphosphonates in metastatic breast cancer. Semin Radiat Oncol 2000;10:250-3.
17. Macklis RM, Cornelli H, Lasher J. Brief courses of palliative radiotherapy for metastatic bone pain: a pilot cost-minimization comparison with narcotic analgesics. Am J Clin Oncol 1998;21:617-22.
18. Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999;52:101-9.
19. Rose CM, Kagan AR. The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys 1998;40:1117-24.
20. Bates T, Yarnold JR, Blitzer P, Nelson OS, Rubin P, Maher J. Bone metastases consensus statement. Int J Radiat Oncol Biol Phys 1992;23:215-16.
21. Madsen EL. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy x 6 versus 10 Gy x 2. Int J Radiat Oncol Biol Phys 1983;9:1775-9.
22. Niewald M, Tkocz HJ, Abel U, et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int J Radiat Oncol Biol Phys 1996;36:1085-9.
23. Gaze MN, Kelly CG, Kerr GR, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol 1997;45:109-16.
24. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
25. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 1985;55:1468-72.
26. Barton MB, Dawson R, Jacob S, Currow D, Stevens G, Morgan G. Palliative radiotherapy of bone metastases: an evaluation of outcome measures. J Eval Clin Pract 2001;7:47-64.
27. O'Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 2000;12:141-4.
28. Duncan G, Duncan W, Maher EJ. Patterns of palliative radiotherapy in Canada. Clin Oncol (R Coll Radiol) 1993;5:92-7.
29. Chow E, Danjoux C, Wong R, et al. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol 2000;56:305-14.
30. Mackillop WJ, Zhou S, Groome P, et al. Changes in the use of radiotherapy in Ontario 1984-1995. Int J Radiat Oncol Biol Phys 1999;44:355-62.
31. Lievens Y, Kesteloot K, Rijnders A, Kutcher G, Van den Bogaert W. Differences in palliative radiotherapy for bone metastases within Western European countries. Radiother Oncol 2000;56:297-303.
32. Evans WJ, Will BP, Berthelot JM, Wolfson MC. The economics of lung cancer management in Canada. Lung Cancer 1996;14:19-29.
33. Doyle C, Stockler M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997;15:1000-7.
34. Kirkbride P, Warde P, Panzarella A, et al. A randomised trial comparing the efficacy of single fraction radiotherapy plus ondansetron with fractionated radiation therapy in the palliation of skeletal metastases [abstract 147]. Int J Radiat Oncol Biol Phys 2000;48(3 suppl):185.
35. Wu JS, Whelan T, Bezjak A, Wong R, Johnston M. Meta-analysis of single-fraction versus multi-fraction radiotherapy trials for palliation of painful bone metastases [abstract]. Int J Radiat Oncol Biol Phys 2001;51(suppl 1):53.
36. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
37. Ratanatarathorn V, Powers W, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999;44:1-18.
38. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999; 52:111-21.
39. Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998;47:233-40.